ArticleJournal of translational medicine2026
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn non-small cell lung cancer (NSCLC) patients, antibiotics impair immunotherapy efficacy, while probiotics can enhance it. The relationship between the duration of probiotics and the restoration of immunotherapy efficacy compromised by antibiotics, as well as its potential to enhance immunotherapy outcomes in antibiotic-naive patients, remains unclear. Furthermore, more probiotic types and their mechanisms for improving immunotherapy efficacy need to be identified and elucidated.
methodsThis multicenter study enrolled wild-type NSCLC patients. Clinicopathological features were recorded, focusing on antibiotic and probiotic use and duration. Baseline fecal and blood samples were collected. Gut microbiota were analyzed via 16S rRNA sequencing, and serum metabolites were analyzed through untargeted metabolomics. Flow cytometry was used to explore potential mechanisms.
results524 wild-type NSCLC patients were enrolled in the study, with fecal samples collected from 22 patients. Patients receiving antibiotics alone exhibited poorer PFS and OS. For those receiving antibiotics, the use of probiotics, regardless of duration, led to improved PFS and OS, which were comparable to those of patients in the No antibiotics + No probiotics group. Among the patients who did not receive antibiotics, those who were treated with probiotics for more than 15 days showed improved PFS. Patients with enriched gut microbiota in un-f-Bifidobacterium and roseburia showed better PFS. The frequency of peripheral Th cells was positively associated with the abundance of un-f-Bifidobacterium. There was also a positive correlation between o-Methoxyphenyl sulfate and the gut microbiota that exhibited better immunotherapy efficacy.
conclusionsAntibiotics weaken immunotherapy efficacy in wild-type NSCLC patients. Probiotics, regardless of duration, can restore it. For antibiotic-naive patients, taking probiotics over 15 days can improve immunotherapy efficacy. Certain probiotics, including un-f-Bifidobacterium and Roseburia, may be potential candidates for improving the efficacy of immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.